GeneDx Holdings Corp. (NASDAQ:WGS) Shares Bought by Summit Partners Public Asset Management LLC

Summit Partners Public Asset Management LLC boosted its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 336.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 755,564 shares of the company's stock after buying an additional 582,619 shares during the quarter. GeneDx accounts for 1.1% of Summit Partners Public Asset Management LLC's investment portfolio, making the stock its 12th largest position. Summit Partners Public Asset Management LLC owned approximately 2.75% of GeneDx worth $58,073,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. William Blair Investment Management LLC acquired a new stake in GeneDx during the 4th quarter worth $51,496,000. Lord Abbett & CO. LLC acquired a new position in GeneDx in the fourth quarter valued at $48,458,000. Science & Technology Partners L.P. acquired a new position in GeneDx in the fourth quarter valued at $30,821,000. Zweig DiMenna Associates LLC acquired a new position in GeneDx in the fourth quarter valued at $23,788,000. Finally, Raymond James Financial Inc. acquired a new position in GeneDx in the fourth quarter valued at $20,371,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

WGS has been the topic of a number of recent research reports. Jefferies Financial Group upgraded shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective on the stock in a research note on Friday, May 9th. Guggenheim began coverage on shares of GeneDx in a research note on Thursday. They issued a "buy" rating and a $88.00 price objective on the stock. The Goldman Sachs Group lifted their target price on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. TD Securities lowered their target price on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Finally, Wells Fargo & Company lowered their target price on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, GeneDx has an average rating of "Moderate Buy" and an average target price of $86.75.

Insider Buying and Selling at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 388 shares of the stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $113.09, for a total transaction of $43,878.92. Following the sale, the chief financial officer now directly owns 3,337 shares of the company's stock, valued at approximately $377,381.33. This represents a 10.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Keith A. Meister bought 100,000 shares of the company's stock in a transaction on Thursday, May 8th. The shares were acquired at an average cost of $56.01 per share, for a total transaction of $5,601,000.00. Following the completion of the acquisition, the director now directly owns 3,008,629 shares of the company's stock, valued at $168,513,310.29. This trade represents a 3.44% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 139,390 shares of company stock worth $13,043,288 in the last ninety days. 29.60% of the stock is owned by insiders.

GeneDx Stock Performance

Shares of WGS stock opened at $68.31 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a one year low of $19.16 and a one year high of $117.75. The company has a 50 day moving average price of $87.10 and a 200 day moving average price of $82.61. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -34.85 and a beta of 1.96.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.17. The company had revenue of $87.12 million during the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.